August 31, 2024First All-Female TAVI Trial Shows Excellent Outcomes for Women Receiving Edwards ValvesRead more
August 21, 2024Edwards Lifesciences to Present at the 2024 Wells Fargo Healthcare ConferenceRead more
July 24, 2024Edwards Lifesciences Expands Structural Heart Portfolio With Acquisitions of JenaValve and EndotronixRead more
June 05, 2024Five-Year Data Show Excellent Outcomes for Female and Small Annulus Patients With Edwards TAVRRead more
May 08, 2024Edwards Launches the SAPIEN 3 Ultra RESILIA Valve in Europe With Technology to Enhance DurabilityRead more
April 07, 2024Study of NFL Alumni Cohort Finds Majority Suffer From Heart Disease Without Knowing ItRead more
March 11, 2024Large, Real-world Studies Demonstrate Continued Excellent Outcomes for Patients Receiving Edwards SAPIEN TAVRRead more
February 23, 2024Edwards Lifesciences to Present at the 44th Annual TD Cowen Healthcare ConferenceRead more
February 02, 2024Edwards’ EVOQUE Valve Replacement System First Transcatheter Therapy to Earn FDA Approval for Tricuspid ValveRead more
January 02, 2024Edwards Lifesciences to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceRead more
December 07, 2023EDWARDS LIFESCIENCES OUTLINES GROWTH STRATEGY AT ANNUAL INVESTOR CONFERENCERead more
October 26, 2023CLASP IID ONE-YEAR DATA CONFIRM SAFETY AND EFFICACY OF EDWARDS PASCAL SYSTEM FOR DEGENERATIVE MITRAL REGURGITATIONRead more
October 26, 2023TRISCEND II SIX-MONTH DATA FOR FIRST 150 PATIENTS SUCCESSFULLY DEMONSTRATE SAFETY AND EFFICACY OF EDWARDS EVOQUE SYSTEM FOR SEVERE TRICUSPID REGURGITATIONRead more
October 24, 2023FIVE-YEAR DATA FROM PARTNER 3 TRIAL DEMONSTRATE EXCELLENT SURVIVAL FOR PATIENTS RECEIVING EDWARDS SAPIEN 3 VALVERead more
October 19, 2023EDWARDS EVOQUE TRANSCATHETER TRICUSPID VALVE REPLACEMENT SYSTEM RECEIVES CE MARKRead more
August 28, 2023EDWARDS LIFESCIENCES TO PRESENT AT THE 2023 WELLS FARGO HEALTHCARE CONFERENCERead more
May 17, 2023DATA FROM BENCHMARK REGISTRY DEMONSTRATE IMPROVED TAVR EFFICIENCY WITH PRESERVED PATIENT SAFETYRead more
May 08, 2023EDWARDS' AORTIC VALVE WITH RESILIA TISSUE SHOWS FAVORABLE DURABILITY, SAFETY AND EFFICACY OUTCOMES IN SEVEN YEAR DATARead more
March 06, 2023EDWARDS HIGHLIGHTS NEW DATA AT ACC RELATED TO LIFETIME MANAGEMENT OF AORTIC STENOSISRead more
January 05, 2023EDWARDS LIFESCIENCES TO PRESENT AT THE 41ST ANNUAL J.P. MORGAN HEALTHCARE CONFERENCERead more
December 08, 2022EDWARDS LIFESCIENCES OUTLINES GROWTH STRATEGY AT ANNUAL INVESTOR CONFERENCERead more
November 27, 2022EDWARDS ANNOUNCES ONE-YEAR DATA ON TRANSFEMORAL TRANSCATHETER TRICUSPID VALVE REPLACEMENTRead more
September 17, 2022EDWARDS ANNOUNCES SIX-MONTH DATA CONFIRMING TEER AS SAFE AND EFFECTIVE FOR DMR IN FIRST HEAD-TO-HEAD TRIALRead more
September 15, 2022EDWARDS PASCAL PRECISION TRANSCATHETER VALVE REPAIR SYSTEM RECEIVES FDA APPROVAL FOR DEGENERATIVE MITRAL REGURGITATIONRead more
August 17, 2022EDWARDS PASCAL PRECISION TRANSCATHETER MITRAL AND TRICUSPID VALVE REPAIR SYSTEM RECEIVES CE MARKRead more
May 23, 2022EDWARDS LIFESCIENCES TO PRESENT AT THE BERNSTEIN 38TH ANNUAL STRATEGIC DECISIONS CONFERENCERead more
March 31, 2022EDWARDS MITRIS RESILIA VALVE RECEIVES FDA APPROVAL FOR MITRAL REPLACEMENT SURGERIESRead more
January 05, 2022EDWARDS LIFESCIENCES TO PRESENT AT THE 40TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCERead more
December 20, 2021EDWARDS RECEIVES FDA APPROVAL FOR SAPIEN 3 WITH ALTERRA PRESTENT FOR TRANSCATHETER PULMONIC VALVE REPLACEMENTRead more
December 08, 2021Edwards Lifesciences Outlines Growth Strategy at Annual Investor ConferenceRead more
November 06, 2021Edwards Announces Six-month Data From Transcatheter Tricuspid Replacement ProgramRead more
November 05, 2021TAVR with SAPIEN 3 Demonstrated as Economically Dominant Treatment Strategy Compared to Surgery in Partner 3 AnalysisRead more
August 02, 2021Edwards Lifesciences initiates $100 million social impact investment fund to advance racial equityRead more
July 22, 2021Study Data Presented at TVT on the Economics of Minimalist TAVR, PARTNER 3 Bicuspid TAVRRead more
June 01, 2021Edwards Receives Clearance For Hypotension Prediction Index Software For Noninvasive Acumen IQ CuffRead more
May 18, 2021Clinical Data Updates On Edwards' Transcatheter Mitral, Tricuspid Programs Presented At EuroPCRRead more
May 18, 2021Real-World Data Confirm Excellent Results For Bicuspid Patients Treated With Edwards SAPIEN 3 TAVRRead more
January 31, 2021Edwards RESILIA Tissue Aortic Valve Demonstrates Favorable Safety and Efficacy at Five YearsRead more
December 21, 2020Edwards Treats First Patient In U.S. Clinical Trial Evaluating Minimally Invasive Device For Mitral Valve DiseaseRead more
December 10, 2020Edwards Lifesciences Outlines Growth Strategy At Annual Investor ConferenceRead more
July 15, 2020Edwards' KONECT RESILIA Aortic Valved Conduit Receives FDA Approval For Complex Aortic Valve SurgeriesRead more
July 13, 2020Edwards Lifesciences Agrees To Global Transcatheter Litigation Settlement With AbbottRead more
May 18, 2020Edwards PASCAL Transcatheter Valve Repair System Receives European Approval For Tricuspid RepairRead more
March 28, 2020Edwards Pauses Enrollments In Pivotal Mitral, Tricuspid Trials In Response To Hospitals' Focus On COVID-19Read more
February 24, 2020Edwards Lifesciences To Present At The Cowen 40th Annual Healthcare ConferenceRead more
February 21, 2020Edwards Lifesciences' Every Heartbeat Matters Philanthropic Initiative Expanding To Reach More PatientsRead more
January 08, 2020Edwards Lifesciences To Present At The 38th Annual J.P. Morgan Healthcare ConferenceRead more
December 05, 2019Edwards Lifesciences Outlines Growth Strategy At Annual Investor ConferenceRead more
September 29, 2019Edwards SAPIEN 3 TAVR Demonstrates Significant Health Status Improvements for Low-Risk PatientsRead more
August 28, 2019Edwards Lifesciences To Present At The 2019 Wells Fargo Healthcare ConferenceRead more
June 04, 2019Edwards Lifesciences To Present At The Goldman Sachs 40th Annual Global Healthcare ConferenceRead more
June 03, 2019Edwards Lifesciences Recommends Stockholders Reject "Mini-Tender Offer" By TRC Capital CorporationRead more
May 15, 2019Edwards Lifesciences' Every Heartbeat Matters Charitable Initiative On Track to Impact 1.5 Million Underserved People By 2020Read more
January 15, 2019Boston Scientific, Edwards Lifesciences Agree To Global Litigation SettlementRead more
December 05, 2018Edwards Lifesciences Outlines Growth Strategy At Annual Investor ConferenceRead more
December 03, 2018Edwards Receives Clearance For HemoSphere Platform With Intelligent Decision-Support ToolsRead more
October 08, 2018Edwards Announces Start Of U.S. Study Of Self-Expanding Transcatheter Heart ValveRead more
September 26, 2018Edwards Lifesciences' Philanthropy Exceeds Every Heartbeat Matters Goal To Impact One Million Underserved People Ahead Of ScheduleRead more
August 30, 2018Edwards Lifesciences To Present At The 13th Annual Wells Fargo Healthcare ConferenceRead more
August 02, 2018Edwards Lifesciences To Present at 38th Annual Canaccord Genuity Growth ConferenceRead more
May 24, 2018Edwards Lifesciences To Present At The Bernstein 34th Annual Strategic Decisions ConferenceRead more
May 22, 2018Real-World Evidence Confirms Clinical Trial Outcomes For Patients Treated With Edwards SAPIEN 3 ValveRead more
March 23, 2018Edwards Prevails In U.S. Patent Office Review That Finds Boston Scientific Transcatheter Valve Patent Claims InvalidRead more
March 21, 2018Edwards Completes Enrollment In PARTNER 3 Low-Risk CT Sub-Study, Updates Timeline For SAPIEN 3 Ultra System Launch In EuropeRead more
March 06, 2018Edwards Lifesciences To Present At The Cowen 38th Annual Health Care ConferenceRead more
January 02, 2018Edwards Lifesciences To Present At The 36th Annual J.P. Morgan Healthcare ConferenceRead more